AAO 2021: First-Line Belzupacap Sarotalocan Shows Promise Against Early Choroidal Melanoma
The investigational agent is a laser-activated, viral-like nanoparticle.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.